Canadian Intellectual Property Office Grants Broad Patent For The Use Of Vigabatrin/CPP-109 For The Prevention Of Addiction In Pain Management
CORAL GABLES, Fla., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that the Canadian Intellectual Property Office (CIPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a patent for the use of vigabatrin for the prevention of addiction in pain management.
The patent is broad and includes the use of vigabatrin/CPP-109 in combination with opioids (e.g., oxycodone, hydrocodone) for pain management. By dampening dopamine release and thus, the euphoria associated with opioids, it is hoped that an opioid/vigabatrin combination may lower or prevent addictive liability without adversely affecting pain relief. CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) is Catalyst's lead compound for the treatment of addiction. Opioid abuse is one of the many substance addiction indications covered under Catalyst's exclusive worldwide license to Brookhaven's international and domestic vigabatrin patent portfolio.
On July 9, 2010, Catalyst announced that the European Patent Office had also granted to Brookhaven a European patent for the use of vigabatrin for the prevention of addiction to opioids used in combination with vigabatrin/CPP-109 for pain management.Patrick J. McEnany, Catalyst's Chief Executive Officer, commented, "We are pleased that the CIPO has granted this patent. As we reported on November 10, 2009, a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System received a $1.2 million grant from the U.S. Department of Defense to conduct animal studies using vigabatrin in combination with opiates to effectively manage pain while reducing the potential for opiate addiction. These studies are currently underway, and we look forward to exploring the development of CPP-109, both here and abroad, to manage the addictive liability associated with the use of opioids for pain management." According to data published in the 2009 National Survey of Drug Use and Health (NSDUH) published by the U.S. Substance Abuse and Mental Health Services Agency (SAMHSA), there were 2.2 million new users of prescription pain relievers, which included 584,000 new nonmedical users of OxyContin ® aged 12 or older. About Catalyst Pharmaceutical Partners Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system, such as epilepsy and neuropathic pain. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions, such as opioid abuse and obsessive-compulsive disorders. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy and pain management. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase. For more information about the Company, go to www.catalystpharma.com . Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the Company will ever be granted the right to market CPP-109 for the treatment of addiction to opioids and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CONTACT: Catalyst Pharmaceutical Partners Patrick J. McEnany, Chief Executive Officer (305) 529-2522 email@example.com Brookhaven National Laboratory Karen McNulty Walsh, Principal Media & Communication Specialist (631) 344-8350 firstname.lastname@example.org Rx Communications Group Melody Carey, Co-President (917) 322-2571 email@example.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV